
Genovis Q1 2025 - Interesting outlook but limited near-term visibility

Redeye updates its outlook on Genovis following a Q1 report coming in slightly above our estimates across the board. The enzyme business marked its strongest sales to date (excluding licensing). Although limited visibility continues to weigh on the share price, Genovis' expanding cash position presents an interesting outlook.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Genovis Q1 2025 - Interesting outlook but limited near-term visibility